163 related articles for article (PubMed ID: 9610690)
1. The relation between the growth patterns of gastric carcinoma and the expression of hepatocyte growth factor receptor (c-met), autocrine motility factor receptor, and urokinase-type plasminogen activator receptor.
Taniguchi K; Yonemura Y; Nojima N; Hirono Y; Fushida S; Fujimura T; Miwa K; Endo Y; Yamamoto H; Watanabe H
Cancer; 1998 Jun; 82(11):2112-22. PubMed ID: 9610690
[TBL] [Abstract][Full Text] [Related]
2. Correlation between loss of E-cadherin expression and overexpression of autocrine motility factor receptor in association with progression of human gastric cancers.
Kawanishi K; Doki Y; Shiozaki H; Yano M; Inoue M; Fukuchi N; Utsunomiya T; Watanabe H; Monden M
Am J Clin Pathol; 2000 Feb; 113(2):266-74. PubMed ID: 10664629
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma.
Endo K; Shirai A; Furukawa M; Yoshizaki T
Hum Pathol; 2006 Aug; 37(8):1111-6. PubMed ID: 16867875
[TBL] [Abstract][Full Text] [Related]
4. Relationship between urokinase-type plasminogen receptor, interleukin-8 gene expression and clinicopathological features in gastric cancer.
Lee KH; Bae SH; Lee JL; Hyun MS; Kim SH; Song SK; Kim HS
Oncology; 2004; 66(3):210-7. PubMed ID: 15218312
[TBL] [Abstract][Full Text] [Related]
5. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
6. Correlative studies on uPA mRNA and uPAR mRNA expression with vascular endothelial growth factor, microvessel density, progression and survival time of patients with gastric cancer.
Zhang L; Zhao ZS; Ru GQ; Ma J
World J Gastroenterol; 2006 Jul; 12(25):3970-6. PubMed ID: 16810742
[TBL] [Abstract][Full Text] [Related]
7. Expression of urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 in gastric cancer.
Kawasaki K; Hayashi Y; Wang Y; Suzuki S; Morita Y; Nakamura T; Narita K; Doe W; Itoh H; Kuroda Y
J Gastroenterol Hepatol; 1998 Sep; 13(9):936-44. PubMed ID: 9794194
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of c-met Protein in Gastric Cancer and Role of uPAR as a Therapeutic Target.
Oh HA; Lee G; Kang HJ; Kim YG; Bae SH; Lee JL; Lee KH; Hyun MS; Kim DS
Cancer Res Treat; 2003 Feb; 35(1):9-15. PubMed ID: 26680909
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression of the autocrine motility factor receptor correlates with poor prognosis and promotes metastasis in gastric carcinoma.
Huang Z; Zhang N; Zha L; Mao HC; Chen X; Xiang JF; Zhang H; Wang ZW
Asian Pac J Cancer Prev; 2014; 15(2):989-97. PubMed ID: 24568530
[TBL] [Abstract][Full Text] [Related]
10. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
11. Elevated expression of autocrine motility factor receptor correlates with overexpression of RhoC and indicates poor prognosis in hepatocellular carcinoma.
Wang W; Yang LY; Yang ZL; Peng JX; Yang JQ
Dig Dis Sci; 2007 Mar; 52(3):770-5. PubMed ID: 17265125
[TBL] [Abstract][Full Text] [Related]
12. [The prognostic significance of expression of c-met oncogene and its relation to gastric mucosal lesions].
Zhuang X; Zheng J; Lin S; Sun G; Li Y
Zhonghua Bing Li Xue Za Zhi; 2000 Dec; 29(6):409-11. PubMed ID: 11866940
[TBL] [Abstract][Full Text] [Related]
13. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
15. Expression of urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor and maspin in oral squamous cell carcinoma: Association with mode of invasion and clinicopathological factors.
Yoshizawa K; Nozaki S; Kitahara H; Kato K; Noguchi N; Kawashiri S; Yamamoto E
Oncol Rep; 2011 Dec; 26(6):1555-60. PubMed ID: 21833477
[TBL] [Abstract][Full Text] [Related]
16. Correlation between expression of urokinase-type plasminogen activator receptor and metastasis in gastric carcinoma.
Yonemura Y; Nojima N; Kawamura T; Ajisaka H; Taniguchi K; Fujimura T; Fujita H; Bandou E; Fushida S; Endou Y; Obata T; Sasaki T
Oncol Rep; 1997; 4(6):1229-34. PubMed ID: 21590227
[TBL] [Abstract][Full Text] [Related]
17. Expression of Met protein and urokinase-type plasminogen activator receptor (uPA-R) in papillary carcinoma of the thyroid.
Zanetti A; Stoppacciaro A; Marzullo A; Ciabatta M; Fazioli F; Prat M; Comoglio PM; Baroni CD; Ruco LP
J Pathol; 1998 Nov; 186(3):287-91. PubMed ID: 10211118
[TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator, its receptor, and its inhibitor in gastric adenocarcinoma tissues.
Hong SI; Park IC; Son YS; Lee SH; Kim BG; Lee JI; Lee TW; Kook YH; Min YI; Hong WS
J Korean Med Sci; 1996 Feb; 11(1):33-7. PubMed ID: 8703368
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue.
Pedersen H; Brünner N; Francis D; Osterlind K; Rønne E; Hansen HH; Danø K; Grøndahl-Hansen J
Cancer Res; 1994 Sep; 54(17):4671-5. PubMed ID: 8062262
[TBL] [Abstract][Full Text] [Related]
20. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.
Webb CP; Hose CD; Koochekpour S; Jeffers M; Oskarsson M; Sausville E; Monks A; Vande Woude GF
Cancer Res; 2000 Jan; 60(2):342-9. PubMed ID: 10667586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
